[go: up one dir, main page]

MX9306005A - IBUPROPEN-CAFEINE COMBINATIONS. - Google Patents

IBUPROPEN-CAFEINE COMBINATIONS.

Info

Publication number
MX9306005A
MX9306005A MX9306005A MX9306005A MX9306005A MX 9306005 A MX9306005 A MX 9306005A MX 9306005 A MX9306005 A MX 9306005A MX 9306005 A MX9306005 A MX 9306005A MX 9306005 A MX9306005 A MX 9306005A
Authority
MX
Mexico
Prior art keywords
ibuprofen
ibupropen
cafeine
combinations
lisin
Prior art date
Application number
MX9306005A
Other languages
Spanish (es)
Inventor
Robert T Sims
William Slivka
Robert Mcmahon
Original Assignee
Merck & Co Inc
Mcneil Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Mcneil Ppc Inc filed Critical Merck & Co Inc
Publication of MX9306005A publication Critical patent/MX9306005A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas para el uso en eltratamiento de dolor e inflamación de mamíferos, incluyendo humanos aladministrar composiciones que comprenden (i) una cantidad analgésica yanti-inflamatoria de una sal de (S)-ibuprofeno substancialmente libre de(R)-ibuprofeno en las cuales la sal se selecciona de(S)-ibuprofenm-(S)-lisina y (S-ibuprofen-(R)-lisina; y (ii) una cantidad efectiva en elaumento del alivio del dolor de la cafeína.The invention relates to pharmaceutical compositions for use in the treatment of mammalian pain and inflammation, including humans to administer compositions comprising (i) an analgesic and anti-inflammatory amount of a (S) -ibuprofen salt substantially free of (R) - ibuprofen in which the salt is selected from (S) -ibuprofenm- (S) -lisin and (S-ibuprofen- (R) -lisin; and (ii) an effective amount in increasing caffeine pain relief.

MX9306005A 1992-09-29 1993-09-28 IBUPROPEN-CAFEINE COMBINATIONS. MX9306005A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95342392A 1992-09-29 1992-09-29

Publications (1)

Publication Number Publication Date
MX9306005A true MX9306005A (en) 1995-01-31

Family

ID=25493974

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9306005A MX9306005A (en) 1992-09-29 1993-09-28 IBUPROPEN-CAFEINE COMBINATIONS.

Country Status (6)

Country Link
EP (1) EP0663819A4 (en)
JP (1) JPH08501796A (en)
AU (1) AU5132893A (en)
CA (1) CA2144152A1 (en)
MX (1) MX9306005A (en)
WO (1) WO1994007471A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE151740T1 (en) * 1992-12-02 1997-05-15 Knoll Ag METHOD FOR PRODUCING ESSENTIAL ENANTIOMERS OF PHENYLPROPIONIC ACIDS
EP0717624A1 (en) * 1993-09-07 1996-06-26 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agents and caffeine
JPH0987174A (en) * 1995-09-26 1997-03-31 Kobayashi Pharmaceut Co Ltd Analgesic and anti-inflammatory composition
US6251945B1 (en) * 1999-01-14 2001-06-26 Knoll Aktiengesellschaft Pharmaceutical mixture comprising a combination of a profen and other active compounds
US20090238763A1 (en) * 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
CA2958454A1 (en) * 2014-08-28 2016-03-03 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for the treatment of acute tooth or jaw pain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4420483A (en) * 1982-07-22 1983-12-13 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising ibuprofen and methods of using same
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
US4681897A (en) * 1984-01-16 1987-07-21 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
WO1992005783A1 (en) * 1990-09-28 1992-04-16 Merck & Co., Inc. Ibuprofen-antihistamine combinations

Also Published As

Publication number Publication date
EP0663819A4 (en) 1998-05-27
WO1994007471A1 (en) 1994-04-14
JPH08501796A (en) 1996-02-27
EP0663819A1 (en) 1995-07-26
CA2144152A1 (en) 1994-04-14
AU5132893A (en) 1994-04-26

Similar Documents

Publication Publication Date Title
ES2156839T1 (en) MEDICINAL CONTAINING ALGINATE AND IMPLANT TO TREAT FIBROSIS.
ES2086270T5 (en) METABOLITES OF TERFENADINE AND ITS OPTICALLY PURE ISOMERS TO TREAT ALLERGIC DISORDERS.
ES2072447T3 (en) EXTERNAL ANALGESIC LOTION AND PREPARATION PROCEDURE.
MX9301929A (en) DERIVATIVES OF PIRIMIDINE AND PROCEDURES FOR ITS PREPARATION.
ES2139132T3 (en) PHARMACEUTICAL COMPOSITIONS ACTIVE IN SLEEP DISORDERS THERAPY.
BR9406979A (en) Compound, pharmaceutical composition for treating an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent processes for treating an inflammatory disease and for preparing a pharmaceutically acceptable salt compound use of a non-steroidal anti-inflammatory pharmaceutical composition compound
AR003938A1 (en) TRICYCLIC UREA COMPOUNDS USEFUL FOR THE INHIBITION OF THE FUNCTION OF PROTEIN G AND FOR THE TREATMENT OF PROTEOLYTIC DISEASES, PHARMACEUTICAL COMPOSITION, AND THE USE OF THE SAME FOR THE PREPARATION OF MEDICINES.
DK0607128T4 (en) Drugs and their manufacture and use in the control of pain and / or inflammation in animals and humans
ES2082288T3 (en) THERAPEUTIC COMPOSITIONS FOR INTRANASAL ADMINISTRATION OF KETOROLACO.
ES2165997T3 (en) USE OF A PEDIATRIC PHARMACEUTICAL FORMULATION THAT INCLUDES AMOXYCLINE AND CLAVULANATE.
ES2059965T3 (en) A PROCEDURE FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY DISEASES.
ES2169197T3 (en) PHARMACEUTICAL COMPOSITION THAT INCLUDES AN ALCANOIL L-CARNITINE IN COMBINATION WITH A POLYINSATURED FATTY ACID OF THE OMEGA-3 SERIES FOR THE PREVENTION AND TREATMENT OF LIPID METABOLISM DISORDERS.
BR9406363A (en) Pharmaceutical composition process for the preparation of the same use and process for the treatment of diseases related to gastric acid
ES2075202T3 (en) NEW ARILPIRIDAZINES, THEIR PREPARATION, THEIR USE, AND THE MEDICINES THAT CONTAIN THEM.
ES2128791T3 (en) SPIROCETAL DERIVATIVES, COMPOSITIONS THAT CONTAIN THEM AND THEIR USE AS THERAPEUTIC AGENTS.
MX9304564A (en) COMBINATIONS OF MUSCLE RELAXANT-IBUPROFEN.
ES2100046T3 (en) ANTIPIRETIC AND ANALGESIC COMPOSITIONS CONTAINING OPTICALLY PURE R-KETOROLACO.
ES2130152T3 (en) MEDICINES TO TREAT INFLAMMATORY PAIN OR ANALGESIA CONTAINING A NSAID AND RANITIDINE / BISMUTE CITRATE.
ATE15596T1 (en) PHARMACEUTICAL AGENT.
RU94002337A (en) Pharmaceutical composition, use of gamma-linolenic acid or dihomo-gamma-linolenic acid for damage treatment after irradiation, treatment method
IT1170214B (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PERIPHERAL ARTERIOPATHIES
DK165903C (en) PHARMACEUTICAL PREPARATION AGAINST ACNE
AR004052A1 (en) A COSMETIC OR PHARMACEUTICAL COMPOSITION INCLUDING A BETA-ADRENERGIC AGONIST
IT1282736B1 (en) USE OF P-AMINOPHENOL DERIVATIVES TO PREPARE PHARMACEUTICAL COMPOSITIONS USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
MX9306005A (en) IBUPROPEN-CAFEINE COMBINATIONS.